Heather Wakelee, MD

Heather Wakelee, MD, discusses the efficacy findings from the phase 3 KEYNOTE-671 clinical trial evaluating the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone for patients with early-stage non–small cell lung cancer.

Heather Wakelee, MD, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors in patients harboring an EGFR mutation.

Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.

Heather Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses the evolving role of bevacizumab (Avastin) in the treatment of patients with non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.

Heather Wakelee, MD, discusses the results of the AVAPERL trial.

Heather Wakelee, MD, discusses maintenance therapy for patients with lung cancer.